1. Structural basis of ligand binding modes at the neuropeptide Y Y 1 receptor.
- Author
-
Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, and Wu B
- Subjects
- Arginine chemistry, Arginine metabolism, Arginine pharmacology, Binding Sites, Crystallography, X-Ray, Dihydropyridines pharmacology, Diphenylacetic Acids pharmacology, Humans, Inositol Phosphates metabolism, Ligands, Molecular Docking Simulation, Mutant Proteins chemistry, Mutant Proteins metabolism, Mutation, Neuropeptide Y chemistry, Neuropeptide Y pharmacology, Nuclear Magnetic Resonance, Biomolecular, Phenylurea Compounds pharmacology, Protein Binding, Receptors, Neuropeptide Y agonists, Receptors, Neuropeptide Y metabolism, Structure-Activity Relationship, Substrate Specificity, Arginine analogs & derivatives, Dihydropyridines chemistry, Dihydropyridines metabolism, Diphenylacetic Acids chemistry, Diphenylacetic Acids metabolism, Neuropeptide Y metabolism, Phenylurea Compounds chemistry, Phenylurea Compounds metabolism, Receptors, Neuropeptide Y antagonists & inhibitors, Receptors, Neuropeptide Y chemistry
- Abstract
Neuropeptide Y (NPY) receptors belong to the G-protein-coupled receptor superfamily and have important roles in food intake, anxiety and cancer biology
1,2 . The NPY-Y receptor system has emerged as one of the most complex networks with three peptide ligands (NPY, peptide YY and pancreatic polypeptide) binding to four receptors in most mammals, namely the Y1 , Y2 , Y4 and Y5 receptors, with different affinity and selectivity3 . NPY is the most powerful stimulant of food intake and this effect is primarily mediated by the Y1 receptor (Y1 R)4 . A number of peptides and small-molecule compounds have been characterized as Y1 R antagonists and have shown clinical potential in the treatment of obesity4 , tumour1 and bone loss5 . However, their clinical usage has been hampered by low potency and selectivity, poor brain penetration ability or lack of oral bioavailability6 . Here we report crystal structures of the human Y1 R bound to the two selective antagonists UR-MK299 and BMS-193885 at 2.7 and 3.0 Å resolution, respectively. The structures combined with mutagenesis studies reveal the binding modes of Y1 R to several structurally diverse antagonists and the determinants of ligand selectivity. The Y1 R structure and molecular docking of the endogenous agonist NPY, together with nuclear magnetic resonance, photo-crosslinking and functional studies, provide insights into the binding behaviour of the agonist and for the first time, to our knowledge, determine the interaction of its N terminus with the receptor. These insights into Y1 R can enable structure-based drug discovery that targets NPY receptors.- Published
- 2018
- Full Text
- View/download PDF